S&P Futures
3,634.50+7.25(+0.20%)Dow Futures
29,880.00+52.00(+0.17%)Nasdaq Futures
12,198.00+45.75(+0.38%)
Ligand Pharmaceuticals Incorporated (LGND)
86.54 -0.87 (-1.00%)
After hours: 5:00PM EST
Chart Events
Performance Outlook
| Previous Close | 86.51 |
| Open | 86.00 |
| Bid | 87.35 x 1100 |
| Ask | 87.48 x 900 |
| Day's Range | 85.98 - 87.60 |
| 52 Week Range | 57.24 - 127.80 |
| Volume | 192,455 |
| Avg. Volume | 325,241 |
| Market Cap | 1.406B |
| Beta (5Y Monthly) | 1.53 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.99 |
| Earnings Date | Feb 04, 2021 - Feb 08, 2021 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | Jul 02, 2010 |
| 1y Target Est | 181.67 |
Fair Value
Related Research
- Business Wire
Ligand Announces Clinical and Regulatory Progress by Multiple Partners with OmniAb® Antibodies
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announces clinical and regulatory progress by multiple partners utilizing antibodies from its OmniAb® discovery platform. Two large multinational pharmaceutical companies with a license to OmniAb have reached clinical-development milestones with their programs. The progress by these companies resulted in a total of $4.5 million in milestone payments being earned by Ligand.
- Business Wire
Ligand’s Partner Sedor Pharmaceuticals Receives FDA Approval for SESQUIENT™ for the Treatment of Status Epilepticus in Adult and Pediatric Patients
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) today announced that its partner Sedor Pharmaceuticals, LLC has received approval from the U.S. Food and Drug Administration (FDA) for SESQUIENT, a Captisol-enabledâ„¢ Fosphenytoin (fosphenytoin sodium for injection) for the treatment of status epilepticus in adult and pediatric patients.
- Zacks
Ligand (LGND) Q3 Earnings & Sales Fall Short of Estimates
Ligand (LGND) reports lower-than-expected third-quarter 2020 earnings and revenues. Outlook for 2020 & 2021 also are below expectations. Stock down.
